Betta Pharmaceuticals Co Ltd Asset Resilience Ratio
Betta Pharmaceuticals Co Ltd asset resilience ratio. Betta Pharmaceuticals Co Ltd (300558) has an Asset Resilience Ratio of 0.83% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 300558 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Betta Pharmaceuticals Co Ltd (2011–2025)
Asset resilience ratio of Betta Pharmaceuticals Co Ltd from 2011 to 2025. This chart shows how Betta Pharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. See Betta Pharmaceuticals Co Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Betta Pharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Betta Pharmaceuticals Co Ltd asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥89.23 Million | 0.83% |
| Total Liquid Assets | CN¥89.23 Million | 0.83% |
Asset Resilience Insights
- Limited Liquidity: Betta Pharmaceuticals Co Ltd maintains only 0.83% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Betta Pharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio
Compare Betta Pharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Abbott India Limited
NSE:ABBOTINDIA |
Drug Manufacturers - Specialty & Generic | 53.22% |
|
Shenzhen Salubris Pharmaceuticals Co Ltd
SHE:002294 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Shanxi Zhendong Pharmaceutical
SHE:300158 |
Drug Manufacturers - Specialty & Generic | 10.74% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
Betta Pharmaceuticals Co Ltd Asset Resilience Ratio by Year (2011–2025)
Betta Pharmaceuticals Co Ltd asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Betta Pharmaceuticals Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.62% | CN¥66.00 Million ≈ $9.66 Million |
CN¥10.57 Billion ≈ $1.55 Billion |
-0.73pp |
| 2024-12-31 | 1.35% | CN¥126.44 Million ≈ $18.50 Million |
CN¥9.34 Billion ≈ $1.37 Billion |
+1.35pp |
| 2023-12-31 | 0.01% | CN¥539.50K ≈ $78.95K |
CN¥9.15 Billion ≈ $1.34 Billion |
-3.20pp |
| 2021-12-31 | 3.21% | CN¥201.01 Million ≈ $29.41 Million |
CN¥6.27 Billion ≈ $917.71 Million |
-0.42pp |
| 2020-12-31 | 3.63% | CN¥190.00 Million ≈ $27.80 Million |
CN¥5.24 Billion ≈ $766.87 Million |
+1.64pp |
| 2017-12-31 | 1.98% | CN¥55.00 Million ≈ $8.05 Million |
CN¥2.77 Billion ≈ $405.78 Million |
-43.00pp |
| 2016-12-31 | 44.99% | CN¥975.00 Million ≈ $142.67 Million |
CN¥2.17 Billion ≈ $317.14 Million |
+25.81pp |
| 2015-12-31 | 19.18% | CN¥220.00 Million ≈ $32.19 Million |
CN¥1.15 Billion ≈ $167.85 Million |
+19.10pp |
| 2013-12-31 | 0.08% | CN¥326.79K ≈ $47.82K |
CN¥410.81 Million ≈ $60.11 Million |
-0.10pp |
| 2012-12-31 | 0.18% | CN¥467.81K ≈ $68.46K |
CN¥261.00 Million ≈ $38.19 Million |
-0.02pp |
| 2011-12-31 | 0.20% | CN¥437.30K ≈ $63.99K |
CN¥215.11 Million ≈ $31.48 Million |
-- |
About Betta Pharmaceuticals Co Ltd
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China and internationally. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma… Read more